Arthroscopic Technologies starts to pick up speed in 2021
While the COVID pandemic was still slowing parts of the overall medical device market, the Arthroscopic Technologies market was able to start to pull ahead as case volumes for Arthroscopic Sports Medicine procedures started to climb back towards pre-COVID levels.
The US market for Hemostats and Sealants resumed its growth in Q121 as procedures climbed back towards normal.
While surgical procedures have not fully regained their pre-COVID levels, the US Hemostats and Sealants market grew in Q121 according to SmartTRAK Financial Dashboard. However, it continued to be a tale of two recoveries. CryoLife* and especially JNJ/Ethicon* posted solid gains for the quarter. However, as elective procedures continue to be behind pre-COVID levels, other manufacturers lagged by comparison.
COVID surges dampened procedure volumes in early Q121, but recovery late in the quarter was like a ray of sunshine
Early in 2021, the dark cloud of the COVID-19 resurgence that started in late 2020 continued to loom over the market early in the quarter. Med tech companies and healthcare providers reported procedure volumes being dampened, but with rays of sunshine peeking through late February and early March. During their Q121 earnings call, HCA Healthcare, one of the largest hospital and healthcare systems in the US, reported rebounding surgical and outpatient volumes in March, with outpatient surgery revenues increasing 30%.
The Symposium on Advanced Wound Care, SAWC, the official meeting of the Wound Healing Society, was held virtually May 10-14 and SmartTRAK attended.
Following is a sampling of some of the takeaways from the meeting that were gathered and curated by our expert analysts and sent out to subscribers in our Daily Updates.
S&N featured a session introducing STRAVIX PL, lyopreserved umbilical tissue w/ room temperature storage, while also highlighting GRAFIX PL, GRAFIX and STRAVIX. SAWC Virtual 2021
A 981-pt (1,111-VLUs) non-inferiority, comparative effectiveness study of PuraPly AM (collagen matrix plus PHMB) antimicrobial and Theraskin (cryopreserved cadaveric skin allograft) for use in VLUs found wound closure comparable at 8, 12, 18 and 24 wks. SAWC Virtual 2021 CR-17
LifeNet*
LifeNet featured Dermacell AWM and recently launched Matrion at SAWC. Matrion is a human placental allograft used as a barrier membrane to treat chronic and acute wounds – a naturally intact placental membrane to incorporate the full trophoblast layer. SAWC Virtual 2021
While COVID was still causing roadblocks for the overall medical device market, Soft Tissue Fixation was able to see some light at the end of the tunnel as case volumes for Orthopedic Sports Medicine procedures started to climb back towards pre-COVID levels.
Q1 Soft Tissue Fixation saw positive revenue growth across all segments over the previous year, especially towards the end of the quarter where case volumes started to pick back up compared to the same period last year, when case volumes plummeted due to the start of the COVID pandemic.
Among the many topics covered in the comprehensive Q121 Soft Tissue Fixation Market Recap* are:
SmartTRAK highlights what’s new in orthopedics, sports medicine, wound care, regenerative medicine and neuro therapies, with a spotlight on Depuy Synthes, a subsidiary of J&J. We constantly monitor the worldwide MedTech industry, sifting through the noise to present to our subscribers the most relevant international news, trends, new products, patents, research, financial data and competitor developments in the global life sciences industry.
The following is a sampling of some recent updates covering Depuy Synthes that were compiled, reviewed and posted in real-time by our SmartTRAK analysts.
New Products:
Sure you read the news, a blog or journal or two, but you do you ever truly feel like you know what your competition is up to? SmartTRAK does! We provide real-time market intel on the MedTech industry including trends, news, financial data, competitor developments and more. Our platform is fueled by industry experts, all of whom have had years of previous experience working at some of the biggest players in the industry. Our team knows what's important to you and we keep our eye to the competition 24/7-- so that our subscribers can save time and find all the competitive intel they need in one place.
SmartTRAK currently features profiles on an ever-growing growing list of over 7,000+ products, including product descriptions, classifications, indications, clinical updates, regulatory status, studies, reimbursements, sales and distribution and more. Learn more about SmartTRAK's competitor profiling below:
SmartTRAK also provides up-to-date, detailed company overviews, including the latest intel, revenues and financial outlooks, strategic alliances and more on over 1,100+ companies, and the list is growing daily. New to a particular industry, or looking to expand into new territory? SmartTRAK's company and product profiles can help you get the lay of the land quickly:
A subscription to SmartTRAK provides you with access to our comprehensive coverage of Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapies markets worldwide. In addition, all subscribers receive a Daily Updates email containing the latest need-to-know news curated by our expert analysts. It's the perfect way to start your day! If you would like to learn more about SmartTRAK , or to see if your company subscribes, just click the button below.
It's time to get out there again and re-connect, and SmartTRAK is excited to be attending ISASS21, the International Society for the Advancement of Spine Surgery's 21st annual conference, at the Loews Miami Beach Hotel in South Beach Miami, May 13-15.
SmartTRAK will be represented by Julianne Burns, General Manager, Spine. Please contact us if you would like a meeting.
Click to read some recent SmartTRAKanalysis articles by Julianne that were featured on the blog:
Like the ball whirling around a casino roulette wheel, COVID-19 sent the US Joint Fluid Market players bouncing and spinning off widely, with some landing the year as winners, and others not so much.
Once again COVID-19 sent players spinning at dizzying speed around the roulette wheel, all in hopes that Lady Luck would let them land unscathed for Q420. With the continued pressure from COVID impacting recovery of the healthcare system and business operations, including the US Joint Fluid Replacement, total revenue for Q420 finished lower vs Q419, according to SmartTRAK Financial Dashboard.
Among the many topics covered in the comprehensive Q420/FY20 US Joint Fluid Market Recap* are:
We are excited to announce the addition of the full market view of Orthopedic Pediatrics (US) to the SmartTRAK platform, featuring 3 modules covering Pediatric Trauma, Pediatric Extremities and Pediatric Spine!
Coverage includes:
SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services.